Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Marcy Bolster and Richard Silver.
Connection Strength

1.135
  1. Assessment and management of scleroderma lung disease. Curr Opin Rheumatol. 1999 Nov; 11(6):508-13.
    View in: PubMed
    Score: 0.176
  2. Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum. 1997 Apr; 40(4):743-51.
    View in: PubMed
    Score: 0.147
  3. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. Curr Opin Rheumatol. 1994 Nov; 6(6):642-9.
    View in: PubMed
    Score: 0.124
  4. Lung disease in systemic sclerosis (scleroderma). Baillieres Clin Rheumatol. 1993 Feb; 7(1):79-97.
    View in: PubMed
    Score: 0.110
  5. Ethnic disparities among patients with pulmonary hypertension associated with systemic sclerosis. J Rheumatol. 2007 Jun; 34(6):1277-82.
    View in: PubMed
    Score: 0.074
  6. Racial variation in clinical and immunological manifestations of systemic sclerosis. J Rheumatol. 2006 Feb; 33(2):263-8.
    View in: PubMed
    Score: 0.068
  7. Correlates of depression, including overall and gastrointestinal functional status, among patients with systemic sclerosis. J Rheumatol. 2005 Jan; 32(1):51-7.
    View in: PubMed
    Score: 0.063
  8. Wegener's granulomatosis in patients with rheumatoid arthritis. J Rheumatol. 2003 Sep; 30(9):2064-9.
    View in: PubMed
    Score: 0.057
  9. Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension. Chest. 2000 Oct; 118(4):1077-82.
    View in: PubMed
    Score: 0.047
  10. Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry. J Rheumatol. 2019 02; 46(2):176-183.
    View in: PubMed
    Score: 0.041
  11. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. Clin Exp Rheumatol. 2017 Sep-Oct; 35 Suppl 106(4):106-113.
    View in: PubMed
    Score: 0.036
  12. Cognitive deficits in a murine model of the eosinophilia-myalgia syndrome: a preliminary report. Neurotoxicol Teratol. 1996 Sep-Oct; 18(5):595-601.
    View in: PubMed
    Score: 0.035
  13. A contaminant of L-tryptophan enhances expression of dermal collagen in a murine model of eosinophilia myalgia syndrome. Proc Assoc Am Physicians. 1996 Jul; 108(4):315-22.
    View in: PubMed
    Score: 0.035
  14. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res (Hoboken). 2014 Mar; 66(3):489-95.
    View in: PubMed
    Score: 0.030
  15. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med. 2008 Jan 01; 177(1):91-8.
    View in: PubMed
    Score: 0.019
  16. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007 Nov 15; 176(10):1026-34.
    View in: PubMed
    Score: 0.019
  17. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis. 2007 Dec; 66(12):1641-7.
    View in: PubMed
    Score: 0.018
  18. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum. 2007 May; 56(5):1676-84.
    View in: PubMed
    Score: 0.018
  19. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006 Jun 22; 354(25):2655-66.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.